The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ursodeoxycholic Acid for Liver Disease Associated With Cystic Fibrosis: A Double–Blind Multicenter Trial
Abstract
Liver disease is increasingly recognized as a major cause of morbidity in cystic fibrosis (CF). Preliminary data suggest that ursodeoxycholic acid (UDCA) may be beneficial for treatment of this manifestation. We performed a double–blind, multicenter trial in these patients to establish efficacy and safety of UDCA in terms of the improvement of clinical and nutritional indicators besides standard liver function tests. We also intended to establish whether taurine supplementation has a beneficial effect in patients receiving UDCA. From June to December 1990, we enrolled in 12 centers 55 CF patients with liver disease (39 male subjects; median age, 13.8 years). They were randomly assigned to receive for 1 year one of the following treatments: UDCA (15 mg/kg body weight daily) plus taurine (30 mg/kg body weight daily), UDCA plus placebo, placebo plus taurine, or double placebo. Clinical and laboratory evaluations were performed every 3 months. After 1 year, deterioration of overall clinical conditions, as indicated by the Shwachman–Kulczycki score (SKS), occurred in patients who received placebo but not in those who received UDCA ( P = .025). Patients treated with UDCA also showed an improvement in γ–glutamyl transpeptidase (GGT) ( P = .004) and 5′–nucleotidase ( P = .006) levels. Treatment with taurine was followed by a significant increase in serum prealbumin levels ( P = .053), a trend toward a reduction in fat malabsorption, and no effect on the biochemical profile. No severe side effects occurred with any treatment. Thus, we concluded that UDCA administration improves clinical and biochemical parameters in CF patients with liver disease. Taurine supplementation may be indicated in patients with severe pancreatic insufficiency and poor nutritional status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“UDCA at doses of 20–30 mg/kg/d has been shown to consistently improve serum liver tests [162,163], to stimulate impaired biliary secretion, to improve histological appearance (over 2 years) [164] and nutritional status.”
BackgroundPaumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Yankaskas, J. R., Marshall, B. C., Sufian, B., Simon, R. H., & Rodman, D. (2004) · Chest · doi:10.1378/chest.125.1_suppl.1s · Cited by 579
Zaroff, J. G., Rosengard, B. R., Armstrong, W. F., Babcock, W. D., D’Alessandro, A., Dec, G. W., Edwards, N. M., Higgins, R. S., Jeevanandum, V., Kauffman, M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000025587.40373.75 · Cited by 495
Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
Debray, D., Kelly, D., Houwen, R., Strandvik, B., & Colombo, C. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60006-4 · Cited by 432
Self-citationUrsodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 411
Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome
Colombo, C., Battezzati, P. M., Crosignani, A., Morabito, A., Costantini, D., Padoan, R., & Giunta, A. (2002) · Hepatology · doi:10.1002/hep.1840360613 · Cited by 377
Self-citationYerushalmi, B. (2001) · Hepatology · doi:10.1053/jhep.2001.22702 · Cited by 339
Oxidative stress and liver disease
Zhu, R., Wang, Y., Zhang, L., & Guo, Q. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.00996.x · Cited by 265
Risk assessment for the amino acids taurine, l-glutamine and l-arginine
Shao, A., & Hathcock, J. N. (2008) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2008.01.004 · Cited by 265
Squires, R. H., Ng, V., Romero, R., Ekong, U., Hardikar, W., Emre, S., & Mazariegos, G. V. (2014) · Hepatology · doi:10.1002/hep.27191 · Cited by 254
Metadata
- Authors
- Colombo, C., Battezzati, P. M., Podda, M., Bettinardi, N., & Giunta, A.
- Venue
- Hepatology
- Published
- 1996-06
- Volume
- 23
- Issue
- 6
- Pages
- 1484-1490
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2072193478
- Cited by
- 219
- References
- 2
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.